NCT07070557

Brief Summary

To explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 6, 2025

Completed
9 days until next milestone

Study Start

First participant enrolled

July 15, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 17, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2026

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

July 17, 2025

Status Verified

July 1, 2025

Enrollment Period

7 months

First QC Date

July 6, 2025

Last Update Submit

July 16, 2025

Conditions

Hemodialysis Patient

Outcome Measures

Primary Outcomes (1)

  • Mortality

    The primary outcome measures in the study "High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated with Poor Survival in Patients with Hemodialysis" is :- All-cause mortality, encompassing death from any cause These is the endpoint used to evaluate the prognostic significance of NLR and PLR in hemodialysis patients.

    6 months

Interventions

neutrophil lymphocyte ratio and platelet lymphocyte ratioOTHER

explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients

Eligibility Criteria

Age18 Months+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients on regular hemodialysis

You may qualify if:

  • All cases with age ≥ 18 years from both sexes female and male, having end-stage renal disease (ESRD), who have been on hemodialysis for at least three months and divided to 4 groups according to the median of NLR and PLR

You may not qualify if:

  • Patients aged \< 18 years old.
  • Patient with autoimmune disease.
  • Patient with liver cirrhosis.
  • Patients with immunodeficiency.
  • Patients with malignancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hemodialysis Unit

Sohag, Sohag Governorate, Egypt

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident in internal medicine department

Study Record Dates

First Submitted

July 6, 2025

First Posted

July 17, 2025

Study Start

July 15, 2025

Primary Completion

February 15, 2026

Study Completion

May 1, 2026

Last Updated

July 17, 2025

Record last verified: 2025-07

Locations

EG(1)